Compare KLTR & TLSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KLTR | TLSI |
|---|---|---|
| Founded | 2006 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Medical Specialities |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 218.0M | 270.2M |
| IPO Year | 2021 | 2020 |
| Metric | KLTR | TLSI |
|---|---|---|
| Price | $1.38 | $4.87 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | $3.00 | ★ $7.00 |
| AVG Volume (30 Days) | ★ 210.6K | 95.6K |
| Earning Date | 05-08-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 61.90 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $180,854,000.00 | $45,151,000.00 |
| Revenue This Year | $2.96 | $35.45 |
| Revenue Next Year | $4.96 | $37.58 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | 1.20 | ★ 53.41 |
| 52 Week Low | $1.06 | $2.20 |
| 52 Week High | $2.05 | $7.95 |
| Indicator | KLTR | TLSI |
|---|---|---|
| Relative Strength Index (RSI) | 35.77 | 48.60 |
| Support Level | $1.32 | $4.70 |
| Resistance Level | $1.53 | $5.58 |
| Average True Range (ATR) | 0.05 | 0.28 |
| MACD | -0.02 | -0.02 |
| Stochastic Oscillator | 2.27 | 43.33 |
Kaltura Inc provides live and on-demand video SaaS solutions to thousands of organizations around the world, engaging hundreds of millions of viewers at home, at work, and at school. It also offers specialized industry solutions, including Learning Management System Video, Lecture Capture, and Virtual Classroom for educational institutions, as well as a TV Solution for media and telecom companies. It operates in two reporting segments which are Enterprise, Education, and Technology, and Media and Telecom. The majority of the revenue is derived from Enterprise, Education & Technology. The majority of the revenue is earned from the United States.
TriSalus Life Sciences Inc is an oncology-focused medical technology business integrating its delivery technology with standard-of-care therapies and its investigational immunotherapeutic, nelitolimod, a class C Toll-like receptor 9 (TRL9) agonist, for patients with solid tumors. The company developed Pressure-Enabled Drug Delivery (PEDD) to overcome high intratumoral pressure and off-target delivery. Its 510(k) cleared device, the TriNav Infusion System using PEDD technology, is used for interventional radiology procedures including transarterial radioembolization (TARE) and transarterial chemoembolization (TACE) in patients with primary liver cancer or liver metastases. It has one reportable segment and generates revenue from sales of PEDD infusion systems, principally related to TriNav.